A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) (Willow 1)
A Phase 1 Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of AM0010 in Healthy Adult Subjects
Sponsor: ARMO BioSciences
This PHASE1 trial investigates Healthy Adult Subjects and is currently completed. ARMO BioSciences leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
May 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Jun 2018 — May 2019 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Dec 2017 — Jan 2018 [monthly]
Active Not Recruiting PHASE1
-
Nov 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Oct 2017 — Nov 2017 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Oct 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ARMO BioSciences
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .